keyword
MENU ▼
Read by QxMD icon Read
search

Secukinumab

keyword
https://www.readbyqxmd.com/read/28217871/secukinumab-in-active-rheumatoid-arthritis-a-randomized-double-blind-placebo-and-active-comparator-controlled-phase-3-study
#1
Francisco J Blanco, Rüdiger Möricke, Eva Dokoupilova, Christine Codding, Jeffrey Neal, Mats Andersson, Susanne Rohrer, Hanno Richards
OBJECTIVE: To evaluate the efficacy and safety of secukinumab in patients with active rheumatoid arthritis (RA) who had an inadequate response or intolerance to tumor necrosis factor inhibitors (TNF-inhibitors). METHODS: In this phase 3 study, 551 patients were randomized (1:1:1:1) to receive intravenous secukinumab 10 mg/kg (baseline, weeks 2, 4) followed by subcutaneous secukinumab 150 mg or 75 mg every 4 weeks or abatacept or placebo at the same dosing schedule...
February 19, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28217466/secukinumab-efficacy-and-safety-in-indian-patients-with-moderate-to-severe-plaque-psoriasis-sub-analysis-from-fixture-a-randomized-placebo-controlled-phase-3-study
#2
Ramesh M Bhat, B Leelavathy, Sacchidanand S Aradhya, Maragondanahalli G Gopal, D V S Pratap, Mir Mubashir, Putta Srinivas, Sushil Y Pande, Amit S Thavkar
TITLE: Secukinumab efficacy and safety in Indian patients with moderate-to-severe plaque psoriasis: sub-analysis from FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis), a randomized, placebo-controlled, phase 3 study. BACKGROUND: Evidence has suggested Interleukin (IL)-17A to be an important effector cytokine in the pathogenesis of psoriasis. Here, we report results for an Indian sub-population from a multinational study FIXTURE, designed to assess the safety, tolerability, and long-term efficacy of fully human anti-IL-17A monoclonal antibody secukinumab in patients with moderate-to-severe plaque psoriasis...
January 2017: Indian Dermatology Online Journal
https://www.readbyqxmd.com/read/28197884/therapies-of-early-advanced-and-late-onset-forms-of-axial-spondyloarthritis-and-the-need-for-treat-to-target-strategies
#3
REVIEW
Nurullah Akkoc, Gercek Can, Salvatore D'Angelo, Angela Padula, Ignazio Olivieri
PURPOSE OF REVIEW: This study aims to provide an update on current status of pharmacological therapies in early and advanced stages of axial spondyloarthritis (axSpA), as well as its late onset forms, and to discuss the need for treat to target strategies in this entity. RECENT FINDINGS: Efficacy of TNF inhibitors has been assessed in randomized controlled trials in axSpA, which included patients who had non-radiographic axSpA according to the ASAS classification criteria...
February 2017: Current Rheumatology Reports
https://www.readbyqxmd.com/read/28176964/efficacy-and-safety-of-biological-and-targeted-synthetic-dmards-a-systematic-literature-review-informing-the-2016-update-of-the-asas-eular-recommendations-for-the-management-of-axial-spondyloarthritis
#4
Alexandre Sepriano, Andrea Regel, Désirée van der Heijde, Jürgen Braun, Xenofon Baraliakos, Robert Landewé, Filip Van den Bosch, Louise Falzon, Sofia Ramiro
OBJECTIVES: To update the evidence for the efficacy and safety of (b)biological and (ts)targeted-synthetic disease-modifying anti-rheumatic drugs (DMARDs) in patients with axial spondyloarthritis (axSpA) to inform the 2016 update of the Assessment of SpondyloArthritis international Society/European League Against Rheumatism (ASAS/EULAR) recommendations for the management of axSpA. METHODS: Systematic literature review (2009-2016) for randomised controlled trials (RCT), including long-term extensions, strategy trials and observational studies (the latter was only for safety assessment and a comparator was required)...
2017: RMD Open
https://www.readbyqxmd.com/read/28162025/secukinumab-in-the-treatment-of-psoriasis-an-update
#5
Radomir Reszke, Jacek C Szepietowski
Biological drugs are pharmaceuticals manufactured using biotechnology methods that may target specific cytokines, cytokine receptors or surface molecules, and modulate the immunological response of the organism. Psoriasis is a common cutaneous disease in which biological drugs have been evaluated and widely accepted in clinical practice. Secukinumab is a monoclonal antibody targeting IL-17A which has been extensively researched in clinical trials and registered in treating moderate to severe plaque psoriasis...
February 6, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28149838/anti-il17a-in-axial-spondyloarthritis-where-are-we-at
#6
Peter P Cheung
Knowledge regarding the mechanisms of the IL17-IL23 pathway and its role in spondyloarthritis (SpA) has been pivotal to the development of IL-17 blockade in patients with axial SpA. Previously, only anti-TNF has proven to be clinically efficacious in patients with active disease, despite non-steroidal anti-inflammatory drugs and physiotherapy. However, up to 50% fail to achieve a clinically significant response. Secukinumab, a fully humanized monoclonal antibody targeting IL-17A, has recently been approved for use in patients with active ankylosing spondylitis...
2017: Frontiers in Medicine
https://www.readbyqxmd.com/read/28122071/secukinumab-for-acrodermatitis-continua-of-hallopeau
#7
David Muggli, Julia-Tatjana Maul, Florian Anzengruber, Myriam Wyss Fopp, Alexander A Navarini
No abstract text is available yet for this article.
January 25, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28112279/secukinumab-il-17a-inhibition-to-treat-psoriatic-arthritis
#8
R Speeckaert, N van Geel, J Lambert, L Claeys, J R Delanghe, M M Speeckaert
Interleukin-17A is an important cytokine in the pathogenesis of psoriatic arthritis. Secukinumab is a recombinant, high-affinity, fully human immunoglobulin G1kappa monoclonal antibody with a selective binding and neutralization of interleukin-17A. By providing an alternative mechanism of action to current treatments, secukinumab has shown efficacy in the key clinical domains of psoriatic arthritis. In the present paper, we discuss the role of interleukin-17A as a clinically relevant target in the treatment of psoriatic arthritis, based on preclinical findings, dose-ranging and regimen-finding, randomized, placebo-controlled clinical trials...
November 2016: Drugs of Today
https://www.readbyqxmd.com/read/28111801/secukinumab-administration-by-autoinjector-maintains-reduction-of-plaque-psoriasis-severity-over-52-weeks-results-of-the-randomized-controlled-juncture-trial
#9
J-P Lacour, C Paul, S Jazayeri, P Papanastasiou, C Xu, J Nyirady, T Fox, C Papavassilis
BACKGROUND: User satisfaction is an important factor associated with treatment adherence in chronic diseases including moderate-to-severe psoriasis. OBJECTIVE: To evaluate the efficacy, safety and patient acceptability of 300 and 150 mg secukinumab - a fully human anti-interleukin-17A monoclonal antibody that has demonstrated efficacy in the treatment of patients with moderate-to-severe plaque psoriasis - self-administered by autoinjection. METHODS: Patients with moderate-to-severe plaque psoriasis were randomized to secukinumab 300 mg, secukinumab 150 mg or placebo self-administered by autoinjection at baseline, Weeks 1, 2 and 3 and then every 4 weeks from Week 4 to Week 48...
January 23, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28099816/new-treatment-options-and-emerging-drugs-for-axial-spondyloarthritis-biological-and-targeted-synthetic-agents
#10
Eric Toussirot
Ankylosing spondylitis (AS) and axial spondyloarthritis (ax SpA) are chronic inflammatory diseases mainly involving the axial skeleton. Pharmacological treatments for AS and ax SpA usually include local glucocorticoid injections, NSAIDs and anti-TNFα agents. Since around 30% to 40% of patients are non responders or intolerant to anti-TNFα agents, we need new therapeutic options for AS and ax SpA. Areas covered: This review describes the new biological agents that can be used or are in development for AS or ax SpA as well as emerging synthetic targeted drugs...
February 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28094756/treatment-modifying-factors-of-biologics-for-psoriatic-arthritis-a-systematic-review-and-bayesian-meta-regression
#11
REVIEW
Eric Druyts, Jacqueline B Palmer, Chakrapani Balijepalli, Keith Chan, Mir Sohail Fazeli, Vivian Herrera, Jeroen P Jansen, Jay J H Park, Steve Kanters, Andreas Reimold
OBJECTIVES: The aim of this study was to explore factors that modify treatment effects of non-conventional biologics versus placebo in patients with psoriatic arthritis. METHODS: A systematic literature review and meta-regression was conducted. The biologics included etanercept, infliximab, adalimumab, golimumab, certolizumab, ustekinumab, tocilizumab, anakinra, abatacept, rituximab, and secukinumab. Outcomes included American College of Rheumatology (ACR) 20 and 50, Psoriasis Area Severity Index (PASI) 75, and 36-Item Short Form Health Survey (SF-36) Physical and Mental Component Summaries (PCS and MCS)...
January 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28087133/secukinumab-sustains-early-patient-reported-outcome-benefits-through-1%C3%A2-year-results-from-2-phase-iii-randomized-placebo-controlled-clinical-trials-comparing-secukinumab-with-etanercept
#12
Bruce Strober, Alice B Gottlieb, Bintu Sherif, Patrick Mollon, Isabelle Gilloteau, Lori McLeod, Todd Fox, Margaret Mordin, Ari Gnanasakthy, Charis Papavassilis, Mark G Lebwohl
BACKGROUND: Psoriasis is a chronic condition with negative impact on patients' quality of life that most often requires lifelong effective and safe treatment. OBJECTIVE: This analysis focused on the effect of secukinumab treatment on patient-reported health-related quality of life as assessed by the Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis. METHODS: The proportion of subjects achieving DLQI score 0/1 response at week 24, time to DLQI score 0/1 response, and sustained DLQI score 0/1 response up to week 52 were compared between secukinumab and etanercept...
January 10, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28042732/the-potential-utility-of-tildrakizumab-an-interleukin-23-inhibitor-for-the-treatment-of-psoriasis
#13
Zenas Z N Yiu, Richard B Warren
The approved biologic therapies are effective for the treatment of psoriasis, but have limitations. Tildrakizumab has a different mechanism of action and is a humanized immunoglobulin G1κ that binds to the p19 subunit of IL23. Areas covered: Phase I, II and III clinical trials investigated the pharmacokinetics, efficacy, safety and immunogenicity of tildrakizumab for patients with psoriasis. The mean half-life of tildrakizumab is between 20.2 to 28.2 days. Tildrakizumab achieved a PASI 75 of 66% and 74% at week 16 for the doses of 100 mg and 200 mg respectively in a phase IIb randomised clinical trial (RCT), and PASI 75 of 61%/64% and 62%/66% at week 12 for 100 mg and 200 mg respectively in two phase III RCTs...
January 1, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28042711/the-impact-of-pasi-75-and-pasi-90-on-quality-of-life-in-moderate-to-severe-psoriasis-patients
#14
Michael Abrouk, M Nakamura, T H Zhu, B Farahnik, J Koo, T Bhutani
BACKGROUND: It is well known that psoriasis significantly impacts patients' quality of life (QoL). With the introduction of improved treatment modalities with biologic agents, more patients with moderate to severe psoriasis are able to achieve better results as measured by the Psoriasis Area and Severity Index (PASI). PASI 75 indicates a 75% or greater reduction in PASI scores from baseline and is indicative of excellent disease improvement. With newer biologic agents such as secukinumab, ixekizumab and brodalumab, patients are now capable of achieving PASI 90, introducing additional clinical decisions for physicians when considering treatment options...
January 18, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28026823/anti%C3%A2-cytokine-therapy-for-psoriasis-not-only-tnf%C3%A2-%C3%AE-blockers-overview-of-reports-on-the-effectiveness-of-therapy-with-il%C3%A2-12-il%C3%A2-23-and-t-and-b-lymphocyte-inhibitors
#15
Dominika Wcisło-Dziadecka, Martyna Zbiciak, Ligia Brzezińska-Wcisło, Urszula Mazurek
TNF‑α inhibitors - infliximab, etanercept and adalimumab - can be used in the treatment of psoriasis vulgaris and psoriatic arthritis, along with other inhibitors of proinflammatory cytokines, such as interleukin‑12 (IL‑12) and IL‑23. This paper presents the results of research on the use of biological drugs other than the tumor necrosis factor blockers (TNF‑α), namely inhibitors of IL‑12 and IL‑23 (ustekinumab), T‑cell inhibitors (alefacept and efalizumab), B‑cell inhibitors (rituximab), anti‑IL‑17 agents (secukinumab, ixekizumab, and brodalumab) and IL23p19 inhibitors (guselkumab and tildrakizumab)...
December 8, 2016: Postȩpy Higieny i Medycyny Doświadczalnej
https://www.readbyqxmd.com/read/27990383/biologics-use-in-indian-psoriasis-patients
#16
Murlidhar Rajagopalan, Asit Mital
The biologics currently in use for psoriasis in India are etanercept, infliximab and recently introduced itolizumab and secukinumab. Biosimilars, expected to play a significant role in psoriasis management in future, have also been available for the last few years. Patients with psoriasis may be considered eligible to receive treatment with any of the licensed biologic interventions when they fulfill the eligibility criteria. The decision to proceed with treatment must be made in collaboration with the patient and include a careful assessment of the associated risks and benefits...
November 2016: Indian Dermatology Online Journal
https://www.readbyqxmd.com/read/27984714/il-17-blockade-in-psoriasis
#17
Patrick R Burkett, Vijay K Kuchroo
IL-17A both directly induces and synergizes with other cytokines to promote autoimmune tissue inflammation. Secukinumab and ixekizumab are monoclonal antibodies (mAb) that inhibit interleukin-17A. These two agents were recently approved for treatment of psoriasis, and secukinumab is also approved for treatment of two spondyloarthropathies, psoriatic arthritis and ankylosing spondylitis.
December 15, 2016: Cell
https://www.readbyqxmd.com/read/27981221/successful-use-of-secukinumab-in-pustular-psoriasis
#18
Jensen Yeung, Venus Valbuena
No abstract text is available yet for this article.
November 2016: JAAD Case Reports
https://www.readbyqxmd.com/read/27981219/successful-treatment-of-type-ii-pityriasis-rubra-pilaris-with-secukinumab
#19
Marie-Léa Gauci, Marie Jachiet, Jeremy Gottlieb, Isabelle Madeleine-Chambrin, Michel Rybojad, Martine Bagot, Jean-David Bouaziz
No abstract text is available yet for this article.
November 2016: JAAD Case Reports
https://www.readbyqxmd.com/read/27971733/cost-effectiveness-analysis-of-secukinumab-compared-to-current-biologics-sequences-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-in-france
#20
E Duteil, C Cariou, A Schmidt, K Benjamin, J Duco
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
30575
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"